Recently a new model for the interaction of sevoflurane propofol and remifentanil was developed. The potency of any combination of the three drugs is defined as probability that a subject tolerates laryngoscopy without movement response. The model allows to compare the potency of intravenous and inhalation anesthetics. If the model is valid also for other stimuli than laryngoscopy and for other responses (e.g. blood pressure or heart rate increase upon stimulation). If the model is valid equipotent concentrations of sevoflurane and propofol the same remifentanil concentration would be sufficient to suppress hemodynamic response to a given stimulus. This will be investigated it the study.

开始日期2015-12-01

申办/合作机构

Insel Gruppe AG

100 项与 SPR1 相关的临床结果

登录后查看更多信息

100 项与 SPR1 相关的转化医学

登录后查看更多信息

100 项与 SPR1 相关的专利（医药）

登录后查看更多信息

项与 SPR1 相关的文献（医药）

2017-11-01·Bioresource technology1区 · 工程技术

Development of simultaneous nitrification-denitrification (SND) in biofilm reactors with partially coupled a novel biodegradable carrier for nitrogen-rich water purification

1区 · 工程技术

Article

作者: Mu, Jun ; Yang, Guangfeng ; Zhao, Jing ; Feng, Lijuan ; Dai, Jincheng

Development of simultaneous nitrification-denitrification (SND) is a promising approach for nitrogen-rich water purification. Coupling biofilm reactors with novel biodegradable carrier of Pumelo Peel (PP) and various conventional plastic fillers (polyurethane filler, SPR-1 suspension filler, TA-II elastic filler and sphere filler) were examined to achieve SND in this study. Results represented that partially coupled with PP could achieve highly efficient SND. Optimal performance appealed in a bioreactor of coupling PP and SPR-1filler with ammonia and total nitrogen removal efficiencies of 96.8±4.0% and 78.9±9.5%, respectively, as well as low effluent COD_Mn of 1.85±0.86mgL^-1. Notably, PP and conventional plastic filler played obviously different roles in combined bioreactor system. Microbial analysis suggested that dominant genera were Thiothrix, Gemmata, unclassified comanonadaceae, unclassified Rhizobiales, Salipiger, Chloronema and Klebsiella in optimal combined bioreactor, which indicated novel co-existence of heterotrophic nitrification, solid-phase, non-solid-phase heterotrophic and sulfur-based autotrophic denitrification for achieving efficient SND.

项与 SPR1 相关的新闻（医药）

2024-03-06

·BioSpace

Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2024

HOUSTON--(BUSINESS WIRE)-- Sporos BioDiscovery, Inc. (a portfolio company of Sporos Bioventures, LLC.), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, today announced that it will present two posters highlighting preclinical data from the company’s novel TEAD1 / TEAD4 isoform selective inhibitor, SPR1, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA. “We look forward to presenting two posters at this year’s AACR meeting that highlight the significant preclinical work we have done to characterize SPR1 as a potential best-in-class TEAD inhibitor. In addition, our team’s expert biological analysis has uncovered a new therapeutic vulnerability that could broaden the potential use of SPR1, a TEAD1/4 inhibitor, to a new subset of cancers with certain homozygous deletions,” said Stephen Rubino, Ph.D., President of Sporos BioDiscovery. Presentation Details: Title: TEAD1/4 inhibitors exhibit deeper biological impact and broader activity compared to TEAD1-only inhibitors in both monotherapy and combination without additional kidney toxicity Session Category: Experimental and Molecular Therapeutics Session Title: New Targets Session Date and Time: Tuesday Apr 9, 2024, 1:30 p.m. - 5:00 p.m. PT Abstract Number: 5913 Poster Number: 27 Title: VGLL4 is the target of the 3p25 homozygous deletion and presents a novel therapeutic vulnerability for TEAD1/4 but not TEAD1 inhibitors Session Category: Experimental and Molecular Therapeutics Session Title: YAP/TAZ/TEAD Modulators Session Date and Time: Wednesday Apr 10, 2024, 9:00 a.m. - 12:30 p.m. PT Abstract Number: 7266 Poster Number: 3 About Sporos BioDiscovery Sporos BioDiscovery, Inc. is a biotechnology research & development company with a diversified pipeline of several small molecule precision oncology therapeutic programs in development, including its lead candidate SPR1, a novel TEAD inhibitor program. Sporos BioDiscovery, Inc. is a portfolio company of Sporos Bioventures, LLC, a private biotechnology company focused on transforming the drug development process across oncology.

AACR会议

2023-03-15

·BioSpace

Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2023

HOUSTON--(BUSINESS WIRE)-- Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, LLC. “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, today announced that it will present a poster highlighting preclinical data from the company’s novel, isoform selective TEAD inhibitor, SPR1, at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14-19, 2023, in Orlando, FL. "We look forward to presenting preclinical data on our TEAD inhibitor, which we believe has best-in-class potential based on its optimized TEAD isoform selectivity pro resultant preclinical activity superior to that of other compounds in development,” said Stephen Rubino, Ph.D., Sporos’ Chief Executive Officer. “SPR1 inhibitors show single-agent activity against multiple TEAD-dependent cell lines in vitro and in vivo, including a range of non-NF2 mutation cell lines and those cell lines that are simply YAP-hyperactive. In addition, our differentiated TEAD inhibitors have demonstrated potent synergistic activity in combination with inhibitors of the MAPK pathway, creating the potential for broad applicability across a number of cancers with serious unmet medical need.” Presentation Details: Title: A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy Session Category: Experimental and Molecular Therapeutics Session Title: New Drug Targets Session Date and Time: Sunday Apr 16, 2023, 1:30 PM - 5:00 PM Abstract Number: 445 About Sporos BioDiscovery Sporos BioDiscovery, Inc. is a biotechnology research & development company with a diversified pipeline of several small molecule precision oncology therapeutic programs in development, including its lead candidate SPR1, a novel TEAD inhibitor program. Sporos BioDiscovery, Inc. is a wholly-owned affiliate company of Sporos Bioventures, LLC, a private biotechnology company focused on transforming the drug development process across oncology.

AACR会议

100 项与 SPR1 相关的药物交易

登录后查看更多信息